Biotech Companies Hit Investment Milestones by Outsourcing to Expert Partner

The stakes are high for biotech companies. It is expensive to acquire equipment and hire skilled scientists while the risk of failure is at every stage.

The risk is reduced if drug discovery and development is accelerated. An expert partner with a fully-functioning team of skilled scientists can help biotech companies reach their financing milestones and get their products to market quickly.

"An outsourcing partner can help companies shorten the drug discovery and development timeline, so they reach investment milestones." Says Peter Pekos, President of Dalton Pharma Services. "Also they reduce their burn rate."

Dalton has a well-integrated team of 90 world-leading chemists. One of Dalton’s customers says, "When we pass off a product to Dalton we know that it’s going into the hands of a team that has worked together for years. They function at a much higher level than a provisional team, pieced together for a single initiative."

Taking a product through the phases of development typically requires biotech companies outsource to a variety of different partners. Vice President of Development for a European biotech said, "Outsourcing a la carte involves many transitions between suppliers. It delays timelines and increases costs." Dalton has added sterile fill facilities to its cGMP manufacturing, and is now able to remove one more "pass of the baton" and in so doing, speeds time to market for its customers.

The VP of a biotech company that is now in late stage trials reports, "Dalton was able to produce our active ingredient at a fraction of the cost we had originally budgeted."

The fill capabilities compliment Dalton’s 42,000 square feet of research and kilo scale production laboratories, analytical labs with HPLC, GC, FTIR, NIR, KF, CE, NMR, UV, and state-of-the-art cGMP

manufacturing suites. With a particular strength in small molecule, peptide synthesis, oligonucleotide sterile fill, manufacture of active pharmaceutical ingredients (API) all under cGMP, Dalton is able to provide a wide spectrum of services for its customers.

"Dalton’s chemists are highly skilled. They were able to reproduce our process and chemistry enabling us to secure the investment capital that we thought we mightn’t ever see," reports one Canadian client with a drug in phase three clinical trials.

Since 1986, Dalton has evolved from a chemistry laboratory to a full service provider; a one-stop- shop for it’s clients who now have the convenience of dealing with one organization from the start to finish of their drug development process.

Hence, in 2005 the company changed its name from Dalton Chemical Laboratories to Dalton Pharma Services to recognize its growing specialization in drug discovery and development.

Contract Research
--